论文部分内容阅读
目的:探讨利福布丁治疗耐多药结核病的临床疗效。方法:选取来我院门诊及住院治疗的耐多药肺结核病患者作为观察对象,并随机分为两组,治疗方案分为3个月强化治疗,6个月巩固治疗,9个月继续治疗,对照组强化期给予利福平+帕司烟肼+左氧氟沙星+乙胺丁醇+丙硫异烟胺+丁胺卡那霉素,巩固期减去丁胺卡那霉素,继续治疗期减去乙胺丁醇,观察组使用利福布丁替换利福平,比较两组患者治疗效果。结果:两组患者治疗后症状、疗效较治疗前均有所好转,其中观察组患者改善更为明显,较对照组有统计学差异。经过18个月治疗后,观察组痰菌阴转率及病灶吸收率显著高于对照组。治疗后,观察组不良反应发生情况明显少于对照组患者。结论:在联合用药治疗耐多药结核病患者时,联合使用利福布丁方案疗效优于联用利福平组,值得进一步深究。
Objective: To investigate the clinical efficacy of rifabutin in the treatment of multidrug-resistant tuberculosis. Methods: Patients with MDR-TB were selected as observation subjects and randomly divided into two groups. The treatment regimen was divided into three months of intensive treatment, 6 months of consolidation treatment, 9 months of continuous treatment, The control group was given rifampicin plus paclitaxel + levofloxacin + ethambutol + propylthiouracil plus amikacin during the intensive phase, minus the amikacin during the consolidation phase, and the treatment period was subtracted Ethambutol, the observation group used rifabutin instead of rifampicin to compare the therapeutic effect of the two groups of patients. Results: After treatment, the symptoms and the curative effects of the two groups were better than those before treatment. The improvement of the observation group was more obvious than that of the control group. After 18 months of treatment, the observation group sputum negative conversion rate and the absorption rate was significantly higher than the control group. After treatment, adverse reactions in the observation group were significantly less than those in the control group. Conclusions: The combination therapy with rifabutin in the treatment of multidrug-resistant tuberculosis patients is superior to the combination of rifampin and warrant further investigation.